No quick cure for Amryt Pharma investors

Cathal Friel


IN A complete shift of gear, Cathal Friel has turned Fastnet Oil & Gas into Amryt Pharmaceuticals. At first sight, moving from a failing oil and gas business into a pharmaceutical operation specialising in ‘orphan’ drug development seems simply bizarre. Friel, who is both the chairman and largest shareholder in Fastnet, with a 12% stake,... Read more »

To access this content, you must be a Phoenix subscriber.

Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!

Subscribe Now! I'm a Subscriber